Deal making in the biosimilars market: increasing investment for decreasing return?
This article was originally published in Scrip
Biosimilars are big business. The global biologics market reached $125 billion in 2011, and is predicted to top $150 billion by the end of 2016. Of this, roughly $60 billion will be in off-patent sales.